🔗 Share this article US and UK Secure Zero-Tariff Deal on Drugs. Conceptual image of medicine exports. Britain and America have signed a major bilateral deal that will ensure zero import taxes on UK medicine exports being sold in the US market. Agreement Details of the Accord In exchange for the tariff guarantee, the UK has committed to raise spending on pharmaceuticals through the NHS. This commitment secures that tariffs on these key products will be held at zero for a timeframe of the next three years. This agreement is in response to previous threats to dramatically increase import taxes on patented pharmaceutical imports, with increases mentioned as high as one hundred percent. "This deal with the UK strengthens the international landscape for innovative medicines and brings much-needed equity to U.S.–U.K. medicine commerce," a release noted. Trade Impact Drugs are one of the Britain's biggest goods shipped to the America, which is by far the biggest market for major UK drugmakers. Export figures show that in the one-year period to the end of the third quarter, the UK shipped pharmaceutical products worth £11.1bn to the US. This amount made up nearly one-fifth of British export trade in that timeframe. "This agreement safeguards work, boosts funding and facilitates the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary commented. Specific British Pledges The pact includes several specific changes from the British government: Higher Cost Ceiling: The UK will raise the cost ceiling at which it judges new medicines to be too expensive by a quarter. Higher Drug Budget: There is a target to raise total health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period. Rebate Cap: The percentage manufacturers must return to the NHS to stay within budget will be capped at fifteen percent. Last year, refunds topped twenty percent. Broader Context The pact comes amid a ongoing dispute between the pharmaceutical industry and the British authorities over drug pricing and approval rates. These tensions were exacerbated by assertions that American customers were charged several times more for the same drugs than people in the other developed nations. In recent months, several large pharmaceutical investments in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been announced toward US facilities. A senior figure publicly accepted that the NHS must spend more on drugs, noting that its budget allocation on drugs had declined as a share of its resources over the previous ten-year period.
Conceptual image of medicine exports. Britain and America have signed a major bilateral deal that will ensure zero import taxes on UK medicine exports being sold in the US market. Agreement Details of the Accord In exchange for the tariff guarantee, the UK has committed to raise spending on pharmaceuticals through the NHS. This commitment secures that tariffs on these key products will be held at zero for a timeframe of the next three years. This agreement is in response to previous threats to dramatically increase import taxes on patented pharmaceutical imports, with increases mentioned as high as one hundred percent. "This deal with the UK strengthens the international landscape for innovative medicines and brings much-needed equity to U.S.–U.K. medicine commerce," a release noted. Trade Impact Drugs are one of the Britain's biggest goods shipped to the America, which is by far the biggest market for major UK drugmakers. Export figures show that in the one-year period to the end of the third quarter, the UK shipped pharmaceutical products worth £11.1bn to the US. This amount made up nearly one-fifth of British export trade in that timeframe. "This agreement safeguards work, boosts funding and facilitates the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary commented. Specific British Pledges The pact includes several specific changes from the British government: Higher Cost Ceiling: The UK will raise the cost ceiling at which it judges new medicines to be too expensive by a quarter. Higher Drug Budget: There is a target to raise total health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period. Rebate Cap: The percentage manufacturers must return to the NHS to stay within budget will be capped at fifteen percent. Last year, refunds topped twenty percent. Broader Context The pact comes amid a ongoing dispute between the pharmaceutical industry and the British authorities over drug pricing and approval rates. These tensions were exacerbated by assertions that American customers were charged several times more for the same drugs than people in the other developed nations. In recent months, several large pharmaceutical investments in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been announced toward US facilities. A senior figure publicly accepted that the NHS must spend more on drugs, noting that its budget allocation on drugs had declined as a share of its resources over the previous ten-year period.